Inhibition of B cell growth factor (BCGF) by monoclonal antibodies directed against the C3d receptor (CR2)

R. T. Perri, B. S. Wilson, Neil Elliot Kay

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Normal human B cell proliferation is controlled by various immunoregulatory signals including the T cell-derived lymphokine B cell growth factor (BCGF). Human BCGF provides the final proliferative signal to normal, activated B cells. We herein show that anti-CR2 monoclonal antibodies inhibit human B cell responsiveness to purified BCGF. Addition of anti-CR2 antibody, AB5, was capable of completely inhibiting BCGF-mediated enhancement of either anti-μ or staphylococcal protein A-activated human B cells (191 ± 21 cpm vs. 3942 ± 622 cpm, mean ± SEM). Inhibition of B cell response to BCGF by AB5 occurred in a dose-dependent manner. Monoclonal antibody anti-B2, which recognizes the same 140-kDa glycoprotein as AB5, in comparable concentrations also inhibited B cell responsiveness to BCGF. Monoclonal antibodies of the same subclass (IgG1) showed no inhibitory effect on BCGF enhancement of B cell proliferation. The F(ab')2 fragment of AB5 generated by pepsin digestion was similarly inhibitory as was the intact Ig. AB5-mediated inhibition was independent of the target B cell state of activation. Both resting and activated B cells (anti-μ or staphylococcal protein A activated) incubated with similar concentrations of AB5 were unresponsive to BCGF. The ability of anti-CR2 antibodies to block BCGF-dependent B cell proliferation suggests that occupancy of C3d membrane receptors may result in modulation of B cell proliferation in physiologic or clinical disease states.

Original languageEnglish (US)
Pages (from-to)350-355
Number of pages6
JournalEuropean Journal of Immunology
Volume16
Issue number4
StatePublished - 1986
Externally publishedYes

Fingerprint

Complement 3d Receptors
Intercellular Signaling Peptides and Proteins
B-Lymphocytes
Monoclonal Antibodies
Cell Proliferation
Staphylococcal Protein A
Anti-Idiotypic Antibodies

ASJC Scopus subject areas

  • Immunology

Cite this

Inhibition of B cell growth factor (BCGF) by monoclonal antibodies directed against the C3d receptor (CR2). / Perri, R. T.; Wilson, B. S.; Kay, Neil Elliot.

In: European Journal of Immunology, Vol. 16, No. 4, 1986, p. 350-355.

Research output: Contribution to journalArticle

@article{2fbe42521d7146d1b86973a0ccac3e21,
title = "Inhibition of B cell growth factor (BCGF) by monoclonal antibodies directed against the C3d receptor (CR2)",
abstract = "Normal human B cell proliferation is controlled by various immunoregulatory signals including the T cell-derived lymphokine B cell growth factor (BCGF). Human BCGF provides the final proliferative signal to normal, activated B cells. We herein show that anti-CR2 monoclonal antibodies inhibit human B cell responsiveness to purified BCGF. Addition of anti-CR2 antibody, AB5, was capable of completely inhibiting BCGF-mediated enhancement of either anti-μ or staphylococcal protein A-activated human B cells (191 ± 21 cpm vs. 3942 ± 622 cpm, mean ± SEM). Inhibition of B cell response to BCGF by AB5 occurred in a dose-dependent manner. Monoclonal antibody anti-B2, which recognizes the same 140-kDa glycoprotein as AB5, in comparable concentrations also inhibited B cell responsiveness to BCGF. Monoclonal antibodies of the same subclass (IgG1) showed no inhibitory effect on BCGF enhancement of B cell proliferation. The F(ab')2 fragment of AB5 generated by pepsin digestion was similarly inhibitory as was the intact Ig. AB5-mediated inhibition was independent of the target B cell state of activation. Both resting and activated B cells (anti-μ or staphylococcal protein A activated) incubated with similar concentrations of AB5 were unresponsive to BCGF. The ability of anti-CR2 antibodies to block BCGF-dependent B cell proliferation suggests that occupancy of C3d membrane receptors may result in modulation of B cell proliferation in physiologic or clinical disease states.",
author = "Perri, {R. T.} and Wilson, {B. S.} and Kay, {Neil Elliot}",
year = "1986",
language = "English (US)",
volume = "16",
pages = "350--355",
journal = "European Journal of Immunology",
issn = "0014-2980",
publisher = "Wiley-VCH Verlag",
number = "4",

}

TY - JOUR

T1 - Inhibition of B cell growth factor (BCGF) by monoclonal antibodies directed against the C3d receptor (CR2)

AU - Perri, R. T.

AU - Wilson, B. S.

AU - Kay, Neil Elliot

PY - 1986

Y1 - 1986

N2 - Normal human B cell proliferation is controlled by various immunoregulatory signals including the T cell-derived lymphokine B cell growth factor (BCGF). Human BCGF provides the final proliferative signal to normal, activated B cells. We herein show that anti-CR2 monoclonal antibodies inhibit human B cell responsiveness to purified BCGF. Addition of anti-CR2 antibody, AB5, was capable of completely inhibiting BCGF-mediated enhancement of either anti-μ or staphylococcal protein A-activated human B cells (191 ± 21 cpm vs. 3942 ± 622 cpm, mean ± SEM). Inhibition of B cell response to BCGF by AB5 occurred in a dose-dependent manner. Monoclonal antibody anti-B2, which recognizes the same 140-kDa glycoprotein as AB5, in comparable concentrations also inhibited B cell responsiveness to BCGF. Monoclonal antibodies of the same subclass (IgG1) showed no inhibitory effect on BCGF enhancement of B cell proliferation. The F(ab')2 fragment of AB5 generated by pepsin digestion was similarly inhibitory as was the intact Ig. AB5-mediated inhibition was independent of the target B cell state of activation. Both resting and activated B cells (anti-μ or staphylococcal protein A activated) incubated with similar concentrations of AB5 were unresponsive to BCGF. The ability of anti-CR2 antibodies to block BCGF-dependent B cell proliferation suggests that occupancy of C3d membrane receptors may result in modulation of B cell proliferation in physiologic or clinical disease states.

AB - Normal human B cell proliferation is controlled by various immunoregulatory signals including the T cell-derived lymphokine B cell growth factor (BCGF). Human BCGF provides the final proliferative signal to normal, activated B cells. We herein show that anti-CR2 monoclonal antibodies inhibit human B cell responsiveness to purified BCGF. Addition of anti-CR2 antibody, AB5, was capable of completely inhibiting BCGF-mediated enhancement of either anti-μ or staphylococcal protein A-activated human B cells (191 ± 21 cpm vs. 3942 ± 622 cpm, mean ± SEM). Inhibition of B cell response to BCGF by AB5 occurred in a dose-dependent manner. Monoclonal antibody anti-B2, which recognizes the same 140-kDa glycoprotein as AB5, in comparable concentrations also inhibited B cell responsiveness to BCGF. Monoclonal antibodies of the same subclass (IgG1) showed no inhibitory effect on BCGF enhancement of B cell proliferation. The F(ab')2 fragment of AB5 generated by pepsin digestion was similarly inhibitory as was the intact Ig. AB5-mediated inhibition was independent of the target B cell state of activation. Both resting and activated B cells (anti-μ or staphylococcal protein A activated) incubated with similar concentrations of AB5 were unresponsive to BCGF. The ability of anti-CR2 antibodies to block BCGF-dependent B cell proliferation suggests that occupancy of C3d membrane receptors may result in modulation of B cell proliferation in physiologic or clinical disease states.

UR - http://www.scopus.com/inward/record.url?scp=0022649187&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0022649187&partnerID=8YFLogxK

M3 - Article

VL - 16

SP - 350

EP - 355

JO - European Journal of Immunology

JF - European Journal of Immunology

SN - 0014-2980

IS - 4

ER -